Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study

Table 2 Chemotherapy related toxicities according to CTCAE (Grade I/II) comparing cycles of mSTF (n = 56) with cycles of NC (n = 62)

	NC	mSTF	PE ± SD*	95% CI	P-Value
Infection	2 (3.4%)	4 (7.3%)	0.07 ± 0.04	0.01–0.15	0.097
Fatigue	22 (37.9%)	25 (45.5%)	-0.01 ± 0.09	− 0.20 – 0.17	0.882
Insomnia	2 (3.4%)	4 (7.3%)	0.03 ± 0.04	− 0.05 – 0.11	0.505
Headaches^a	2 (5.7%)	0	−0.03 ± 0.06	− 0.14 – 0.09	0.649
Dizziness^a	3 (8.6%)	2 (7.1%)	−0.10 ± 0.07	−0.25 – 0.05	0.187
Depression	2 (3.4%)	2 (3.6%)	− 0.02 ± 0.04	− 0.10 – 0.06	0.560
Nausea	22 (37.9%)	16 (29.1%)	− 0.01 ± 0.10	−0.21 – 0.18	0.895
Vomiting	0	2 (3.6%)	0.02 ± 0.03	−0.03 – 0.08	0.413
Diarrhea	2 (3.4%)	2 (3.6%)	−0.01 ± 0.04	−0.09 – 0.07	0.877
Obstipation^b	5 (8.8%)	4 (7.3%)	−0.02 ± 0.06	−0.13 – 0.09	0.688
Stomach pains^a	1 (2.9%)	0	−0.02 ± 0.04	−0.10 – 0.07	0.695
Reduced appetite^a	7 (20.0%)	2 (7.1%)	−0.16 ± 0.11	−0.39 – 0.06	0.150
Hunger^c	2 (5.6%)	0	−0.03 ± 0.06	−0.15 – 0.09	0.606
Stomatitis	15 (25.9%)	3 (5.5%)	−0.16 ± 0.06	−0.28 – (− 0.03)	0.013
Esophagitis	2 (3.4%)	2 (3.6%)	0.01 ± 0.04	− 0.08 – 0.09	0.892
Neuroses	8 (13.8%)	10 (18.2%)	0.07 ± 0.07	−0.06 – 0.20	0.280
Arthralgia	1 (1.7%)	2 (3.6%)	0.02 ± 0.03	−0.05 – 0.09	0.614
Pain	11 (19%)	3 (5.5%)	− 0.11 ± 0.06	−0.23 – 0.01	0.075
Dyspnea	0	2 (3.6%)	0.03 ± 0.02	− 0.01 – 0.07	0.098
Oedemas	0	1 (1.8%)	0.0 ± 0.02	−0.04 – 0.04	0.840

Values are shown as mean ± SD. Due to missing data, we included data of 58 cycles of NC and 55 cycles of mSTF in this analysis.*PE ± SD represents the difference for CTCAE points between cycles of NC and those of mSTF. All side effects were scored according to CTCAE v.4.0. Each side effect was scored once per patient during each chemotherapy cycle. a n = 63; b n = 112; c n = 64

ISSN: 1471-2407